NASDAQ:ENTO Entero Therapeutics (ENTO) Stock Price, News & Analysis $0.42 +0.01 (+2.47%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends About Entero Therapeutics Stock (NASDAQ:ENTO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Entero Therapeutics alerts:Sign Up Key Stats Today's Range$0.39▼$0.4250-Day Range$0.31▼$0.7452-Week Range$0.19▼$14.51Volume27,416 shsAverage Volume360,085 shsMarket Capitalization$1.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEntero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Read More… Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Entero Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks17th Percentile Overall ScoreENTO MarketRank™: Entero Therapeutics scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Entero Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Entero Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.52) per share.Price to Book Value per Share RatioEntero Therapeutics has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.03% of the float of Entero Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntero Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entero Therapeutics has recently decreased by 68.22%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntero Therapeutics does not currently pay a dividend.Dividend GrowthEntero Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.03% of the float of Entero Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntero Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Entero Therapeutics has recently decreased by 68.22%, indicating that investor sentiment is improving significantly. News and Social Media1.0 / 5News Sentiment-0.17 News SentimentEntero Therapeutics has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Entero Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for ENTO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $214.00 in company stock.Percentage Held by InsidersOnly 0.49% of the stock of Entero Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 12.30% of the stock of Entero Therapeutics is held by institutions.Read more about Entero Therapeutics' insider trading history. Receive ENTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTO Stock News Headlines$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTONovember 15, 2024 | globenewswire.comEntero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO ForumNovember 14, 2024 | finance.yahoo.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 21, 2024 | WealthPress (Ad)SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of ShareholdersNovember 14, 2024 | globenewswire.comShareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public ShareholdersNovember 13, 2024 | businesswire.comENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to ShareholdersNovember 13, 2024 | businesswire.comEntero Therapeutics announces proposed reverse merger with Journey TherapeuticsNovember 13, 2024 | markets.businessinsider.comEntero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical CompanyNovember 13, 2024 | globenewswire.comSee More Headlines ENTO Stock Analysis - Frequently Asked Questions How have ENTO shares performed this year? Entero Therapeutics' stock was trading at $2.94 at the beginning of 2024. Since then, ENTO shares have decreased by 85.9% and is now trading at $0.4150. View the best growth stocks for 2024 here. How were Entero Therapeutics' earnings last quarter? Entero Therapeutics, Inc. (NASDAQ:ENTO) posted its quarterly earnings data on Monday, October, 21st. The company reported ($3.37) earnings per share (EPS) for the quarter. How do I buy shares of Entero Therapeutics? Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Entero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include Conduit Pharmaceuticals (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), Elevai Labs (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST). Company Calendar Last Earnings10/21/2024Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTO CUSIPN/A CIK1604191 Webwww.enterothera.com Phone561-589-7020FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.06% Return on Assets-12.01% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book0.23Miscellaneous Outstanding Shares4,750,000Free Float4,731,000Market Cap$1.91 million OptionableN/A Beta1.22 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ENTO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.